Compare Aehr Test Systems (AEHR) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs BioNTech SE - ADR — how do they compare? Aehr Test Systems trades at $132.42 (market cap $3.82B), while BioNTech SE - ADR trades at $93.06 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 6.1× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| AEHR | BNTX | |
|---|---|---|
Market Cap | $3.82B | $23.31B |
Sector | Technology | Health |
52-Week High | $117.18 | $119.34 |
52-Week Low | $17.38 | $83.89 |
Enterprise Value | $3.72B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR Test Systems stock trades at $129.70, up 22.13% in the past 24 hours, with a bullish technical signal from moving averages and strong momentum. Recent earnings beats and a $22 million AI processor order (Accesswire, August 12, 2026) highlight growth potential, though negative net income margins and high P/S of 71.87 reflect valuation concerns amid rapid revenue expansion.
Outlook is mixed: strong AI-driven demand and record bookings support upside, but profitability challenges, insider selling, and customer concentration pose risks. Analyst consensus is cautious with 33% buy ratings, indicating tempered optimism despite technical strength.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
